IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Tiedemann Advisors LLC

Share on StockTwits

Tiedemann Advisors LLC lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 83.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 850 shares of the company’s stock after selling 4,174 shares during the quarter. Tiedemann Advisors LLC’s holdings in IDEXX Laboratories were worth $234,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Nomura Asset Management Co. Ltd. increased its holdings in IDEXX Laboratories by 506.8% in the 2nd quarter. Nomura Asset Management Co. Ltd. now owns 131,696 shares of the company’s stock worth $36,260,000 after buying an additional 109,992 shares during the period. AXA boosted its position in IDEXX Laboratories by 167.3% in the 2nd quarter. AXA now owns 97,903 shares of the company’s stock worth $26,956,000 after purchasing an additional 61,279 shares in the last quarter. Scotia Capital Inc. purchased a new stake in IDEXX Laboratories in the 2nd quarter worth approximately $276,000. APG Asset Management N.V. boosted its position in IDEXX Laboratories by 32.3% in the 2nd quarter. APG Asset Management N.V. now owns 28,700 shares of the company’s stock worth $6,939,000 after purchasing an additional 7,000 shares in the last quarter. Finally, Captrust Financial Advisors boosted its position in IDEXX Laboratories by 32.5% in the 2nd quarter. Captrust Financial Advisors now owns 151 shares of the company’s stock worth $42,000 after purchasing an additional 37 shares in the last quarter. Hedge funds and other institutional investors own 87.04% of the company’s stock.

In related news, Director Sophie V. Vandebroek sold 9,044 shares of the firm’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $263.86, for a total transaction of $2,386,349.84. Following the completion of the transaction, the director now directly owns 12,116 shares in the company, valued at approximately $3,196,927.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Giovani Twigge sold 2,300 shares of the firm’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $274.44, for a total value of $631,212.00. The disclosure for this sale can be found here. Insiders have sold a total of 73,305 shares of company stock valued at $19,402,442 over the last three months. Corporate insiders own 2.70% of the company’s stock.

Several equities research analysts have commented on the company. Canaccord Genuity restated a “buy” rating and issued a $285.00 price objective on shares of IDEXX Laboratories in a research report on Friday, August 2nd. Goldman Sachs Group initiated coverage on IDEXX Laboratories in a research report on Monday, September 9th. They set a “neutral” rating and a $277.00 target price on the stock. Credit Suisse Group increased their target price on IDEXX Laboratories from $282.00 to $293.00 and gave the company an “outperform” rating in a research report on Friday, August 16th. Guggenheim initiated coverage on IDEXX Laboratories in a research report on Thursday, May 23rd. They set a “buy” rating and a $276.00 target price on the stock. Finally, BidaskClub lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 10th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. IDEXX Laboratories presently has an average rating of “Buy” and an average price target of $285.29.

IDXX stock traded down $5.58 during midday trading on Friday, reaching $265.47. The stock had a trading volume of 343,980 shares, compared to its average volume of 369,301. The company’s fifty day simple moving average is $278.73 and its 200 day simple moving average is $253.27. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 4.49. The company has a market cap of $23.33 billion, a price-to-earnings ratio of 62.32 and a beta of 0.85. IDEXX Laboratories, Inc. has a 52-week low of $176.11 and a 52-week high of $292.17.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Thursday, August 1st. The company reported $1.43 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.06. IDEXX Laboratories had a return on equity of 765.45% and a net margin of 17.78%. The company had revenue of $620.10 million for the quarter, compared to analyst estimates of $627.10 million. During the same quarter last year, the firm posted $1.23 EPS. The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 4.86 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

See Also: What is the NASDAQ Stock Market?

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.